Tips

美迪西匯總整理了3月生物醫(yī)藥行業(yè)會(huì)議供參考交流。同時(shí)，我們將計(jì)劃參與海內(nèi)外8場(chǎng)會(huì)議：

IVC2024第四屆核酸疫苗與創(chuàng)新疫苗研發(fā)工藝論壇

IVC2024第四屆核酸疫苗與創(chuàng)新疫苗研發(fā)工藝論壇將于2024年3月1-2日在上海盛大召開：80余位專家學(xué)者，1000位行業(yè)同行邀您共襄盛會(huì)，2天3個(gè)會(huì)場(chǎng)全力打造疫苗盛宴。

2024（第四屆）類器官大會(huì)

為推動(dòng)國際類器官領(lǐng)域的發(fā)展，促進(jìn)研究人員深入交流合作，探討類器官研究領(lǐng)域的關(guān)鍵科學(xué)問題，2024（第四屆）類器官大會(huì)—類器官與新藥研發(fā)暨ISoOR 2024國際類器官高峰論壇將于2024年3月7-8日在中國上海雅居樂萬豪侯爵酒店召開。

第七屆成都生物醫(yī)藥創(chuàng)新者峰會(huì)

美迪西首席科學(xué)官彭雙清教授將擔(dān)任論壇主持嘉賓，毒理研究部高級(jí)主任鄒漢軍博士將出席GLP1藥物開發(fā)論壇并發(fā)表主題演講。

第七屆成都生物醫(yī)藥創(chuàng)新者峰會(huì)將于2024年3月7-8日于成都舉辦，會(huì)議將涵蓋ADC，改良型新藥，小分子新藥，GLP-1藥物研發(fā)領(lǐng)域前沿動(dòng)態(tài)，并聚焦最新臨床進(jìn)展。旨在打破行業(yè)的信息壁壘，推動(dòng)創(chuàng)新多元發(fā)展！屆時(shí)美迪西商務(wù)團(tuán)隊(duì)將在A01展位等候您的蒞臨。

第九屆細(xì)胞生物產(chǎn)業(yè)大會(huì)

細(xì)胞生物產(chǎn)業(yè)作為戰(zhàn)略性新興產(chǎn)業(yè)，近年來不斷獲得政策的支持和市場(chǎng)的青睞。2023更是細(xì)胞生物領(lǐng)域取得重大突破的一年，發(fā)改委對(duì)外發(fā)布的《產(chǎn)業(yè)結(jié)構(gòu)調(diào)整指導(dǎo)目錄（2024年本）》，鼓勵(lì)細(xì)胞產(chǎn)業(yè)的發(fā)展，預(yù)示著我國細(xì)胞生物產(chǎn)業(yè)正在與全球前沿接軌。細(xì)胞生物產(chǎn)業(yè)在2023年的表現(xiàn)，為市場(chǎng)環(huán)境重振了信心，也為更多的研究立項(xiàng)帶來期待和轉(zhuǎn)機(jī)。

于此背景下，第九屆細(xì)胞生物產(chǎn)業(yè)大會(huì)暨第七屆中國生物醫(yī)藥創(chuàng)新合作大會(huì)將于2024年3月8-9日在深圳盛大開幕！本次大會(huì)由深圳市細(xì)胞治療技術(shù)協(xié)會(huì)、正和會(huì)展聯(lián)合組織，助力細(xì)胞生物產(chǎn)業(yè)創(chuàng)新發(fā)展，合作共贏！

SOT 63rd Annual Meeting and ToxExpo

More Science, More Networking, More Everything in 2024

Medicilon is excited to attend and exhibit at the conference. Dr. Haizhou Zhang, president of preclinical R&D unit at Medicilon, will be available at the booth. Dr. Zhang holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.

Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones.

14th World ADC London

Europe's Longest Standing & Definitive Antibody-Drug Conjugate Event！

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development.

In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon started ADC non-clinical research in 2014. As of the end of 2023, We has successfully assisted in the clinical approval of 20+ ADC drugs by NMPA and/or FDA and has 30+ ADC projects under development.

2024 NEDMDG Spring Meeting

Recent interest in the delivery of therapeutics to the brain has dramatically increased with the advent of new ADCs and other targeted delivery vehicles for the treatment of dementias and glioblastoma. In addition, subcutaneous delivery has been found to be an effective mode of ADC delivery, but the bioavailability in humans has been difficult to predict. These two factors have driven an increasing interest in the human cell-based in vitro models for screening novel delivery methods to gain mechanistic insight into the factors that control either entry into the brain or systemic bioavailability of subcutaneously delivered drugs. In this presentation Dr. Roger Kamm will present the models specifically developed for both applications and the potential for iPS cell-derived systems. The benefits and current limitations of these models will also be addressed with the goal of stimulating an active discussion.

The Seminar is Sponsored by Medicilon.

IDC2024

從當(dāng)前“創(chuàng)新”布局來看，內(nèi)卷嚴(yán)重，靶點(diǎn)扎堆，同質(zhì)化競(jìng)爭激烈：內(nèi)卷之中如何做到扶搖直上九萬里而不被卷入旋渦，卻成了創(chuàng)新藥人當(dāng)下最需要考慮的一點(diǎn)。

BIOCHINA2024(EBC)

美迪西新分子類型專場(chǎng)將于3月16日在大會(huì)期間舉行，美迪西毒理研究部副總裁曾憲成博士與毒理研究部高級(jí)主任鄒漢軍博士受邀出席并發(fā)表主題演講。

BIOCHINA2024第九屆易貿(mào)生物產(chǎn)業(yè)展覽(EBC)將于2024年3月14-16日在蘇州國際博覽中心ABCDEFG館召開。

BIOCHINA2024(EBC)全新起航，以“展覽-大會(huì)-活動(dòng)”三大體系，規(guī)模30,000人、550家展商、500場(chǎng)學(xué)術(shù)報(bào)告。屆時(shí)美迪西商務(wù)團(tuán)隊(duì)將在C3館C060-C061展位等候您的蒞臨。

ACS Spring 2024

Many Flavors of Chemistry！

Founded in 1876 and chartered by the U.S. Congress, ACS is one of the world's largest scientific organizations with more than 200,000 individuals in its global community across 140 countries.

With the rapid development of the global pharmaceutical market and the division of labor in the industry, the process of drug discovery and development is becoming increasingly refined. This makes specialized outsourcing an important strategic choice for pharmaceutical companies. In the early stages, companies often use FTE models for the synthesis of structural fragments and candidate compounds to accelerate the drug screening process. Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and we offer cooperation through both FFS and FTE models.

2024美迪西創(chuàng)新藥物產(chǎn)業(yè)生態(tài)合作大會(huì)

2004年，美迪西成立。

回首廿載，美迪西始終專注一站式臨床前研發(fā)服務(wù)平臺(tái)建設(shè)，與中國創(chuàng)新藥企業(yè)攜手同行，共同見證行業(yè)的發(fā)展與蛻變。

2024年，為進(jìn)一步推動(dòng)中國新藥事業(yè)的高質(zhì)量發(fā)展，美迪西創(chuàng)新藥物產(chǎn)業(yè)生態(tài)合作大會(huì)將于2024年3月18日在上海舉行。500余位行業(yè)精英共聚滬上，為創(chuàng)新藥物產(chǎn)業(yè)生態(tài)建言獻(xiàn)策，共同探索中國醫(yī)藥企業(yè)合作發(fā)展新機(jī)遇。

BIO-Europe Spring

Connecting the global biopharma community to elevate life science partnerships

BIO-Europe Spring, the premier springtime partnering event, brings together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings.

Medicilon provides comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world. Based on the key requirements of drug R&D, we focus on meeting the demand for innovation and development. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry. By the end of 2023, we have served more than 2000 clients globally with more than 300 INDs approved in China and more than 80 INDs approved overseas.

SIT 2024第六屆小分子藥物創(chuàng)新與合作大會(huì)

本屆大會(huì)內(nèi)容將聚焦小分子藥物的創(chuàng)新開發(fā)、立項(xiàng)策略、生產(chǎn)與MAH、轉(zhuǎn)化醫(yī)學(xué)、合作共贏、PROTAC、共價(jià)抑制劑、PPI、變構(gòu)抑制劑、多肽偶聯(lián)藥物、多肽減重藥物、 AI與CADD助力新藥開發(fā)及其他新技術(shù)等，跨越小分子藥物研發(fā)的熱點(diǎn)領(lǐng)域，一覽當(dāng)下化學(xué)創(chuàng)新藥研發(fā)新動(dòng)向，致力于打破行業(yè)的封閉循環(huán)，破除行業(yè)內(nèi)卷，助推創(chuàng)新多元發(fā)展!一切盡在小分子藥物的年度產(chǎn)業(yè)大會(huì)!

SABPA Event

8th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum

SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: GLP-1, ADC, and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.

2024生物藥創(chuàng)新與質(zhì)量大會(huì)

生物藥是目前最具投資價(jià)值的醫(yī)藥細(xì)分領(lǐng)域，在全球在研藥物整體中的比例逐年上升。伴隨國家各類醫(yī)藥政策的扶持和資本的孵化，中國生物醫(yī)藥創(chuàng)新迎來了新的歷史機(jī)遇。

生物醫(yī)藥研發(fā)與創(chuàng)新相關(guān)技術(shù)的進(jìn)步是生物醫(yī)藥產(chǎn)業(yè)發(fā)展的基礎(chǔ)。為推動(dòng)生物醫(yī)藥產(chǎn)業(yè)發(fā)展，更好地促進(jìn)生物技術(shù)產(chǎn)學(xué)研交流，由中國食藥促進(jìn)會(huì)檢驗(yàn)檢定分會(huì)、四川省生物化學(xué)與分子生物學(xué)學(xué)會(huì)、四川省藥學(xué)會(huì)藥物分析專業(yè)委員會(huì)和四川省藥學(xué)會(huì)生物藥物專業(yè)委員會(huì)主辦，藥檢匯聯(lián)合主辦，由杭州奇易科技有限公司承辦的“BIQC2024生物藥創(chuàng)新與質(zhì)量大會(huì)”將于2024年3月在成都舉行。大會(huì)以“創(chuàng)新引領(lǐng)高質(zhì)量發(fā)展”為主題，搭建合作交流平臺(tái)，聚焦國家發(fā)改委“十四五”生物經(jīng)濟(jì)發(fā)展規(guī)劃，探討新時(shí)代變革中生物醫(yī)藥產(chǎn)業(yè)發(fā)展的新思路、新路徑。圍繞mRNA疫苗、多肽藥物、抗體偶聯(lián)等前沿生物技術(shù)、生物藥研發(fā)創(chuàng)新與質(zhì)量控制展開深入交流和研討。

第二屆中國生物藥分析與質(zhì)量峰會(huì)

隨著生物藥技術(shù)的不斷發(fā)展，藥物的類型越來越多，我國的生物藥研發(fā)與生產(chǎn)也進(jìn)入到一個(gè)快速增長的時(shí)期。

生物藥的分子量大、空間結(jié)構(gòu)嚴(yán)格、修飾形式和變異體多樣等特點(diǎn)，給藥物分析與質(zhì)量控制帶來了巨大挑戰(zhàn)。血清、血漿、唾液、尿液和組織等生物基質(zhì)中藥物濃度測(cè)定是藥物研發(fā)的重要環(huán)節(jié)，科學(xué)的生物分析方法對(duì)于藥物藥代動(dòng)力學(xué)、毒代動(dòng)力學(xué)、生物等效性等藥物的臨床前研究提供依據(jù)。理化、雜質(zhì)、生物學(xué)活性、免疫學(xué)特性及相關(guān)的表征研究等非常復(fù)雜，科學(xué)的質(zhì)量管理與控制體系是生物藥研發(fā)及生產(chǎn)重點(diǎn)關(guān)注與探討的方向。生物藥分析與質(zhì)量峰會(huì)BioAQ是藥物分析、質(zhì)量及監(jiān)管方面重要的交流平臺(tái)，致力于促進(jìn)生物醫(yī)藥行業(yè)產(chǎn)、學(xué)、研技術(shù)交流與合作。峰會(huì)圍繞當(dāng)下生物藥發(fā)展趨勢(shì)和監(jiān)管要求，對(duì)單抗、雙/多抗、重組/融合蛋白、細(xì)胞治療、基因治療、核酸藥物等的生物分析方法與質(zhì)量控制進(jìn)行分享和深入探討。

marketing@medicilon.com.cn
微信或郵件聯(lián)系我們